Condition: Huntington Disease · Sponsor: King's College London
iMarkHD is an adaptive, longitudinal positron emission tomography (PET) and magnetic resonance (MR) imaging study in Huntington's disease (HD) that aims to assess abnormal molecular, functional, and structural changes in participants' brains, ranging from several years before symptom onset to the advanced symptom stage. The study will be conducted over a three (3) year period (Baseline, Year-1, and Year-2).
This description comes directly from the study's public registry record.
Steve Williams, PhD · 0044-(0)-203-228-3063 · steve.williams@kcl.ac.uk
Daniel J van Wamelen, PhD · 0044-(0)-203-228-3084 · daniel.van_wamelen@kcl.ac.uk
Always discuss trial participation with your own doctor first.
| King's College London | London, England, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03434548